FDA approve Alimta & Keytruda for combination lung cancer treatment

The US regulators have approved a combination of Eli Lilly’s Alimta and MSD’s Keytruda as first-line treatment for patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), irrespective of PD-L1 expression status. The combination was approved via the FDA’s accelerated approval pathway based on Phase II tumour response rate and progression-free survival (PFS) data observed

Continue Reading